Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?
Saved in:
| Title: | Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies? |
|---|---|
| Authors: | Janardhan SV; Center for Liver Diseases, Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, Chicago, IL, USA., Reau NS; Center for Liver Diseases, Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, Chicago, IL, USA. |
| Source: | Hepatic medicine : evidence and research [Hepat Med] 2015 Apr 16; Vol. 7, pp. 11-20. Date of Electronic Publication: 2015 Apr 16 (Print Publication: 2015). |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Dove Medical Press Country of Publication: New Zealand NLM ID: 101544801 Publication Model: eCollection Cited Medium: Print ISSN: 1179-1535 (Print) Linking ISSN: 11791535 NLM ISO Abbreviation: Hepat Med Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
